Cheshire CARDIOLOGY

TREATMENT FOR DOGS WITH DEGENERATIVE MITRAL VALVE DISEASE (DMVD) AND STAGE C CONGESTIVE HEART FAILURE (CHF)

PLEASE INFORM YOUR CANINE PATIENTS' OWNERS ABOUT THIS CLINICAL TRIAL

We would like to inform you that Cheshire Cardiology is taking part in a clinical study researching an investigational medicinal product to treat dogs with **diagnosed DMVD and previous CHF**.

OVERVIEW OF THE STUDY

The study duration is 12 months. It is a double-blind, placebo-controlled study in which dog owners administer a **tablet** to their pets orally **once daily.** The goal of the study is to prolong the life of the dogs.

INCLUSION CRITERIA

- **Dog ≥ 6 years of age**
- **BW between 2.5 and 20 kg**
- Diagnosed with **DMVD Stage C** within **the 9 months** prior to inclusion
- **Stabilised CHF**
- Dogs receiving **oral furosemide (≤ 5 mg/kg/day) and pimobendan** (0.1 to 0.3 mg/kg every 12 hours) at stable dosages for at least seven days prior to inclusion.
- Dogs also receiving an **ACE inhibitor with or without spironolactone** can be included. If so, these treatments must be used at stable dosages for at least seven days prior to inclusion.

All of the diagnostic investigations required as part of the study are covered by the study sponsor, including:

Examinations of the heart and respiratory tract
Blood and urine tests
Diagnostic tests including echocardiograms, X-rays of the chest and systolic blood pressure

HOW TO REFER PATIENTS

It's easy to refer your patients. To get more information, just contact us directly and mention the dog study.

Phone: 01606 827188
Email: admin@cheshirecardiology.com
Web: www.cheshirecardiology.com

Find us on: facebook
Follow us on twitter

Cheshire Cardiology,
The Old School House,
Chester Road,
Castle, Northwich
CW8 1LE

Cheshire Cardiology is the trading name for Cheshire Cardiology Ltd
Company Reg. No. 09126851 Registered in England
Full terms and conditions available at www.cheshirecardiology.com/terms-and-conditions